AU2018256453B2 - Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies - Google Patents

Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies Download PDF

Info

Publication number
AU2018256453B2
AU2018256453B2 AU2018256453A AU2018256453A AU2018256453B2 AU 2018256453 B2 AU2018256453 B2 AU 2018256453B2 AU 2018256453 A AU2018256453 A AU 2018256453A AU 2018256453 A AU2018256453 A AU 2018256453A AU 2018256453 B2 AU2018256453 B2 AU 2018256453B2
Authority
AU
Australia
Prior art keywords
tumor
cancer
antibody
cells
plgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018256453A
Other languages
English (en)
Other versions
AU2018256453A1 (en
Inventor
Kazuto FUKUNAGA
Jeffrey A. Hubbell
Ako ISHIHARA
Jun Ishihara
Melody Swartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of AU2018256453A1 publication Critical patent/AU2018256453A1/en
Application granted granted Critical
Publication of AU2018256453B2 publication Critical patent/AU2018256453B2/en
Priority to AU2024202918A priority Critical patent/AU2024202918A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
    • G21F5/00—Transportable or portable shielded containers
    • G21F5/06—Details of, or accessories to, the containers
    • G21F5/12—Closures for containers; Sealing arrangements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
    • G21F7/00—Shielded cells or rooms
    • G21F7/005—Shielded passages through walls; Locks; Transferring devices between rooms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
    • G21F5/00—Transportable or portable shielded containers
    • G21F5/06—Details of, or accessories to, the containers
    • G21F5/14—Devices for handling containers or shipping-casks, e.g. transporting devices loading and unloading, filling of containers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2018256453A 2017-04-20 2018-04-20 Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies Active AU2018256453B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202918A AU2024202918A1 (en) 2017-04-20 2024-05-02 Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487823P 2017-04-20 2017-04-20
US62/487,823 2017-04-20
PCT/US2018/028505 WO2018195386A1 (en) 2017-04-20 2018-04-20 Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202918A Division AU2024202918A1 (en) 2017-04-20 2024-05-02 Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies

Publications (2)

Publication Number Publication Date
AU2018256453A1 AU2018256453A1 (en) 2019-12-05
AU2018256453B2 true AU2018256453B2 (en) 2024-02-08

Family

ID=63856403

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018256453A Active AU2018256453B2 (en) 2017-04-20 2018-04-20 Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies
AU2024202918A Pending AU2024202918A1 (en) 2017-04-20 2024-05-02 Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202918A Pending AU2024202918A1 (en) 2017-04-20 2024-05-02 Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies

Country Status (7)

Country Link
US (2) US11574747B2 (enExample)
EP (1) EP3612209A4 (enExample)
JP (2) JP7419070B2 (enExample)
CN (1) CN111132693A (enExample)
AU (2) AU2018256453B2 (enExample)
MX (1) MX2019012579A (enExample)
WO (1) WO2018195386A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
AU2018256453B2 (en) * 2017-04-20 2024-02-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies
US11732029B2 (en) 2017-11-13 2023-08-22 The University Chicago Methods and compositions for the treatment of wounds
CN112292391A (zh) 2018-03-05 2021-01-29 芝加哥大学 用与细胞因子连接的ecm亲和肽治疗癌症的方法和组合物
CA3105454A1 (en) 2018-07-03 2020-01-09 Catalent Pharma Solutions, Llc Multifunctional protein molecules comprising decorin and use thereof
EP3930687A4 (en) * 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114206355A (zh) * 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
EP4076669A4 (en) * 2019-12-19 2024-01-10 Board of Regents, The University of Texas System METHOD FOR TREATING GLIOBLASTOMA
CN115065734A (zh) * 2021-02-27 2022-09-16 华为技术有限公司 一种数据处理方法、装置及芯片
WO2025203029A1 (en) * 2024-03-28 2025-10-02 Hadasit Medical Research Services And Development Ltd. Tricer - a tri-specific cell engager and retainer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006082A1 (en) * 2012-07-03 2014-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Conjugates containing sequences from placenta growth factor and their use as components of biomaterials and in medicine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086620A (en) 1991-02-14 1992-02-11 Wayne State University Method of microencapsulation of hyperbaric gas
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
FR2707658B1 (fr) 1993-07-12 1995-11-24 Prolabo Sa Latex fluorescent comportant au moins deux fluorochromes, procédé d'obtention et application dudit latex comme marqueur, notamment en biologie.
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
US6106474A (en) 1997-11-19 2000-08-22 Scimed Life Systems, Inc. Aerogel backed ultrasound transducer
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
US6626855B1 (en) 1999-11-26 2003-09-30 Therus Corpoation Controlled high efficiency lesion formation using high intensity ultrasound
JP5074652B2 (ja) 2000-02-08 2012-11-14 ライスユニバーシティ 治療法および診断法において使用される光学活性なナノ粒子
CA2406133A1 (en) 2000-04-17 2001-10-25 Rashid Bashir Biosensor and related method
JP2003532681A (ja) 2000-05-05 2003-11-05 ジーティーシー バイオセラピューティックス インコーポレイテッド 遺伝子導入により産生されたデコリン
KR100396695B1 (ko) 2000-11-01 2003-09-02 엘지.필립스 엘시디 주식회사 에천트 및 이를 이용한 전자기기용 기판의 제조방법
US6939721B2 (en) 2000-12-18 2005-09-06 Agilent Technologies, Inc. Fluorescence immunoassays using organo-metallic complexes for energy transfer
EP1379284A4 (en) 2001-01-05 2007-07-25 Gen Hospital ACTIVE IMAGING PROBES
DE10111458B4 (de) 2001-03-09 2008-09-11 Siemens Ag Analyseeinrichtung
DE10111457B4 (de) 2001-03-09 2006-12-14 Siemens Ag Diagnoseeinrichtung
DE10137530A1 (de) 2001-08-01 2003-02-13 Presens Prec Sensing Gmbh Anordnung und Verfahren zur Mehrfach-Fluoreszenzmessung
US20030104512A1 (en) 2001-11-30 2003-06-05 Freeman Alex R. Biosensors for single cell and multi cell analysis
US6806543B2 (en) 2002-09-12 2004-10-19 Intel Corporation Microfluidic apparatus with integrated porous-substrate/sensor for real-time (bio)chemical molecule detection
US20050107694A1 (en) 2003-11-17 2005-05-19 Jansen Floribertus H. Method and system for ultrasonic tagging of fluorescence
US20080160024A1 (en) * 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
AT504685B1 (de) 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
US10420820B2 (en) 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
EP3356371A4 (en) 2015-09-29 2020-06-24 The University of Chicago POLYMER CONJUGATE VACCINE
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
AU2018256453B2 (en) 2017-04-20 2024-02-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies
US11732029B2 (en) 2017-11-13 2023-08-22 The University Chicago Methods and compositions for the treatment of wounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006082A1 (en) * 2012-07-03 2014-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Conjugates containing sequences from placenta growth factor and their use as components of biomaterials and in medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUI LIANG ET AL: "A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix", SCIENTIFIC REPORTS, vol. 6, no. 1, 17 February 2016 (2016-02-17), XP055747260, DOI: 10.1038/srep18205 *

Also Published As

Publication number Publication date
EP3612209A1 (en) 2020-02-26
US20230377764A1 (en) 2023-11-23
US11574747B2 (en) 2023-02-07
JP7419070B2 (ja) 2024-01-22
MX2019012579A (es) 2020-07-28
EP3612209A4 (en) 2021-03-24
US20200123228A1 (en) 2020-04-23
JP2024041874A (ja) 2024-03-27
JP2020517658A (ja) 2020-06-18
WO2018195386A1 (en) 2018-10-25
US12706227B2 (en) 2026-08-11
AU2024202918A1 (en) 2024-07-18
CN111132693A (zh) 2020-05-08
AU2018256453A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
US20230377764A1 (en) Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies
US20260049115A1 (en) Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines
JP2023025195A (ja) 腫瘍療法のためのｉｌ－１２とｔ細胞阻害分子遮断薬とを含む医薬組成物
JP7004761B2 (ja) 癌治療のための改善された細胞組成物および方法
ES2808153T3 (es) Terapia de combinación para tratamiento de enfermedad
KR20210031479A (ko) Cd137 및 ox40에 결합하는 항체 분자
JP2020522529A (ja) 癌の治療または予防のための薬剤およびその使用
JP2017521410A (ja) Ｉｌ−１５ベース分子及びその使用方法
KR20100091950A (ko) Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
CN104284680A (zh) 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
JP2025121986A (ja) コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
US20220227876A1 (en) Rank antagonists and uses thereof
JP2017538415A (ja) Ａｘｌに対するヒトモノクローナル抗体
BR122026001844A2 (pt) Polipeptídeo compreendendo um peptídeo de afinidade com ecm ligado a citocina, vetor de ácido nucleico e composição compreendendo o dito polipeptídeo, bem como método para preparar o mesmo e uso do mesmo ou da composição para tratar câncer
NZ751584A (en) Antibodies to mica and micb proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)